The patient, who was being treated with an investigational gene therapy for limb-girdle muscular dystrophy, died of acute ...

Our Bureau, Mumbai Friday, July 18, 2025, 17:45 Hrs [IST] ...

These were the most active stocks ahead of Friday's market open: Sarepta Therapeutics Inc.'s stock tumbled 27% after the company said another patient died following gene-therapy treatment, Bloomberg ...

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.

Sarepta Therapeutics Inc. said another patient has died from acute liver failure after receiving one of its gene therapies, ...

Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...

Shares of Sarepta Therapeutics declined 26% to $16.17 in premarket trading on Friday on media reports of a patient death after receiving one of the company's gene therapies, making it the third such ...

ProPublica reporter David Epstein was contacted by a woman with a wild story and a batch of photos she believed were clues to the mystery of her condition. Turns out, she was right.

A gene called SDR42E1 has been identified as a key player in how our bodies absorb and process vitamin D. Researchers found that disabling this gene in colorectal cancer cells not only crippled their ...

Shares of Sarepta Therapeutics declined 16.5% in premarket trading on Friday after a Bloomberg report that a trial patient who received an experimental gene therapy has died from liver failure, making ...

Sarepta Therapeutics (SRPT) said a third patient has died from acute liver failure after receiving one of its gene therapies, ...